Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Vemurafenib Has Durable Activity in NSCLC Harboring BRAF V600 Mutations

Key clinical point: Vemurafenib has durable antitumor activity in patients with BRAF V600–mutant NSCLC.

Major finding: The objective response rate was 37.1% overall (37.5% in previously untreated patients and 37.0% in previously treated patients).

Study details: Phase 2 open-label, single-arm, multicohort trial with analysis of 62 patients having BRAF V600–mutant NSCLC (VE-BASKET trial).

Disclosures: Dr. Subbiah disclosed having a consulting or advisory role with or receiving research funding from numerous pharmaceutical companies. The study was sponsored by Hoffmann–La Roche.


Subbiah V et al. JCO Precis Oncol. 2019 June 27. doi: 10.1200/PO.18.00266.